Background

MetaboHealth represents a novel indicator of overall health in middle age and may potentially be suitable as actionable health check in prevention strategies. MetaboHealth is a blood-based metabolomic composite score that predicts a wide range of age-related conditions and mortality in large European cohorts.

Methods

Here, we investigated whether MetaboHealth can be personalised and limited to clinically validated, i.e. CE-marked, metabolic biomarkers. Next, we assessed whether the updated MetaboHealth score predicts all-cause mortality and cardiometabolic disease incidence and can be improved by a lifestyle intervention. To personalise MetaboHealth, we scaled the metabolic biomarkers using a Dutch reference population (i.e. the Biobanking and BioMolecular Research Infrastructure Netherlands) and, in addition, based the score solely on clinically validated metabolic biomarkers.

Results

The novel version of the score, Personal-MetaboHealth, retained predictive accuracy for all-cause mortality and showed an even stronger association with incident cardiometabolic disease in the Leiden Longevity Study (LLS) in which 2,404 participants were followed for up to 22 and 16 years for mortality and morbidity, respectively. The association of Personal-MetaboHealth with all-cause mortality remained robust after adjusting for smoking quantity, alcohol consumption, and medication use, while the cardiometabolic disease association was attenuated due to smoking quantity. Each unit increase in Personal-MetaboHealth was associated with a 13.69 year later onset of the first cardiometabolic disease in the LLS. Next, we showed that Personal-MetaboHealth can be improved by a 3-month combined lifestyle intervention in middle aged individuals (Growing Old Together study), specifically in those at risk, i.e. with an unhealthy score at baseline.

Conclusions

Personal-MetaboHealth thus offers a potential actionable health check in middle age for early prevention and extension of healthy lifespan.

© 2026. The Author(s).